The PD-1 and PD-L1 inhibitor market
has witnessed significant growth in recent times on account of the increasing
prevalence of various cancers globally. PD-1 and PD-L1 inhibitors help boost
the body's immune system to fight against cancer by blocking proteins called
PD-1 and PD-L1. These proteins help tumours evade the immune system by turning
off T-cells. By blocking these proteins, PD-1 and PD-L1 inhibitors help T-cells
attack the cancer cells. The growing geriatric population prone to developing
various cancers and the emergence of combination therapies have further
propelled the demand for PD-1 and PD-L1 inhibitors.
The Global PD-1 and PD-L1 Inhibitor
Market is estimated to be valued at US$
45.89 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the PD-1 and PD-L1 inhibitor market are Sesajal S.A.
de C.V., Olivado, Grupo Industrial Batellero S.A. de C.V, YASIN, Tron Hermanos
SA de CV, The Village Press, Bella Vado, Chosen Foods LLC, and Storino's
Quality Products. These players are engaged in developing innovative PD-1 and
PD-L1 inhibitor drugs and therapies through extensive research and clinical
trials.
The emerging opportunities in the PD-1
and PD-L1 Inhibitor Market Trends comprise developing combination
therapies through partnerships with pharmaceutical companies. Combining PD-1 or
PD-L1 inhibitors with other immunotherapy drugs, chemotherapies or targeted
therapies can help improve treatment outcomes.
Globally, the key players are focused on expanding their presence in high
growth regions such as North America, Europe, China and Japan. Favourable
reimbursement policies for cancer drugs in the US and growth of healthcare
infrastructure in developing nations will aid the global expansion of PD-1 and
PD-L1 inhibitor market over the forecast period.
Market Drivers
The increasing incidence of various cancers globally is a major driver for the
PD-1 and PD-L1 inhibitor market. According to World Cancer Research Fund, in
2018, around 18 million new cancer cases were reported worldwide. The growing
geriatric population also contributes to the increasing burden of cancer.
The approval and launch of innovative PD-1 and PD-L1 inhibitor drugs along with
combination therapies present lucrative opportunities. For instance, Merck's
Keytruda received FDA approval for lung cancer in 2021.
Market Restraints
However, the high cost of PD-1 and PD-L1 inhibitor drugs remains a major
challenge to widespread adoption especially in price-sensitive developing
markets. Developing biosimilar versions can help reduce the treatment cost.
Serious adverse effects associated with PD-1 and PD-L1 inhibitor therapy such
as lung inflammation, diarrhoea and fatigue also limit their usage in some
patients. Biomarker development for better patient selection is key to
overcoming this restraint.
Segment Analysis
PD-L1 inhibitor segment is expected to be the dominating sub segment during
forecast period as PD-L1 inhibitors are promising and highly effective
treatments for various cancers such as melanoma, non-small cell lung cancer,
renal cell carcinoma and others. PD-L1 inhibitors work by blocking PD-L1
receptor signaling which helps cancer cells to evade the immune system. This
allows immune cells to recognize and destroy cancer cells. Key products such as
Bavencio, Imfinzi, and Tecentriq are driving the growth of this sub segment.
The PD-1 inhibitor segment is also expected to grow at a significant rate
during forecast period owing to increasing adoption of PD-1 inhibitors for
treating cancers that are less responsive to conventional chemotherapy. Drugs
such as Opdivo, Keytruda and Libtayo are boosting the growth of this segment.
However, PD-1 inhibitors are associated with immune related adverse effects
which is limiting its adoption to some extent.
Global Analysis
North America region dominated the global PD-1 and PD-L1 inhibitor market share
in 2024 owing to high adoption of PD-1 and PD-L1 inhibitors in the US for
treating various cancers. Presence of well-established healthcare facilities
and favorable reimbursement policies are also contributing to the growth of
this regional market. Asia Pacific is projected to grow at the fastest pace
during the forecast period due to rising healthcare expenditure, increasing
public awareness about cancer immunotherapy and growing accessibility to cancer
treatments.
0 Comments